National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4. doi: 10.1016/j.chom.2022.03.029. Epub 2022 Mar 25.
The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We used plasma from 20 unvaccinated and 7 vaccinated individuals infected by Omicron BA.1 to test binding, Fc effector function, and neutralization against VOCs. In unvaccinated individuals, Fc effector function and binding antibodies targeted Omicron and other VOCs at comparable levels. However, Omicron BA.1-triggered neutralization was not extensively cross-reactive for VOCs (14- to 31-fold titer reduction), and we observed 4-fold decreased titers against Omicron BA.2. In contrast, vaccination followed by breakthrough Omicron infection associated with improved cross-neutralization of VOCs with titers exceeding 1:2,100. This has important implications for the vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging VOCs. Although Omicron-based immunogens might be adequate boosters, they are unlikely to be superior to existing vaccines for priming in SARS-CoV-2-naive individuals.
新冠病毒奥密克戎变异株逃避了疫苗或感染引发的中和抗体。然而,奥密克戎是否会引发针对其他关注变异株(VOCs)的交叉反应性体液免疫反应尚不清楚。我们使用了 20 名未接种疫苗和 7 名接种疫苗的奥密克戎 BA.1 感染者的血浆,来检测针对 VOCs 的结合、Fc 效应功能和中和能力。在未接种疫苗的个体中,Fc 效应功能和结合抗体对奥密克戎和其他 VOCs 的靶向水平相当。然而,奥密克戎 BA.1 引发的中和反应对 VOCs 的交叉反应性并不广泛(滴度降低 14-31 倍),我们观察到针对奥密克戎 BA.2 的滴度降低了 4 倍。相比之下,接种疫苗后突破性感染奥密克戎与提高对 VOCs 的交叉中和作用相关,其滴度超过 1:2,100。这对未接种疫苗的奥密克戎感染者对循环和新兴 VOCs 的再次感染的易感性具有重要意义。尽管基于奥密克戎的免疫原可能是足够的加强剂,但它们不太可能优于现有的疫苗,在 SARS-CoV-2 初次感染者中发挥作用。
iScience. 2025-7-9
Front Immunol. 2025-6-9
N Engl J Med. 2022-4-21
N Engl J Med. 2022-4-7